Description:

A breakthrough product for the early detection of parietal lobe dysfunction and Alzheimer's disease, the AQT can be used in conjunction with brain imaging and other neuropsychiatric procedures to:

• Support an early differential diagnosis of Alzheimer's disease
• Detect impaired temporo-parietal function

Features and Benefits

Use this test with confidence when assessing you clients.

• Contains rapid, automatic naming (RAN) tasks, verified by rCBF measures to screen for Alzheimer's disease and other parietal impairments

Tasks measure:

1. Processing speed and automaticity of naming
2. Cognitive shifts between visual dimensions and semantic fields
3. Activation of working memory for processing and monitoring
4. Parietal loble dysfunction associated with neurogenic disorders.
   - Objective measures are based on clocked total-naming time
5. Highly reliable (r=.88 - 96) over time and consistent over repeated trials
6. Independent of gender differences, education and cultural linguistic background
7. Enables examiners from other cultural-linguistic communities to develop directions for administration and standards for verbal responses that are representative of their language
8. Allows you to conduct comparative evaluations of monolingual or bilingual adolescents and adults.